SCHEMBL4967200

SCHEMBL4967200

COc1cc(Nc2c(C#N)cnc3cc(Br)c(OC)cc23)c(Cl)cc1Cl

nearest known ligand 0.84

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SRC P12931 20/20 0.84
ABL1 P00519 2/20 0.84
BCR P11274 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5103346 0.96 SRC (0.84) SRCABL1BCR
SCHEMBL5106375 0.93 SRC (0.82) SRCABL1BCR
SCHEMBL22861713 0.91 SRC (1.00) SRCABL1BCR
SCHEMBL13938749 0.88 SRC (0.86) SRCABL1BCR
SCHEMBL29188617 0.87 SRC (0.84) SRCABL1BCR
SCHEMBL2978588 0.87 SRC (0.84) SRCABL1BCR
SCHEMBL3990230 0.87 SRC (0.84) SRCABL1BCR
SCHEMBL5255575 0.87 SRC (0.84) SRCABL1BCR
SCHEMBL24414021 0.86 SRC (0.90) SRCABL1BCR
SCHEMBL3981801 0.86 SRC (0.75) SRCABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7479561-B2 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors WYETH (US) 2009-01-20 US disclosed
EP-1802581-B1 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY WYETH CORP (US) 2008-04-02 EP disclosed
US-20080033175-A1 Process for preparation of 4-amino-3-quinolinecarbonitriles WYETH HOLDINGS CORPORATION (US) 2008-02-07 US disclosed
US-7297795-B2 Process for preparation of 4-amino-3-quinolinecarbonitriles WYETH HOLDINGS CORPORATION (US) 2007-11-20 US disclosed
EP-1802581-A1 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY Wyeth a Corporation of the State of Delaware (US) 2007-07-04 EP disclosed
US-20060116375-A1 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury WYETH (US) 2006-06-01 US disclosed
EP-1660453-A2 PROCESS FOR THE PREPARATION OF 4-AMINO-3-QUINOLINECARBONITRILES Wyeth Holdings Corporation (US) 2006-05-31 EP disclosed
WO-2006047262-A1 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY WYETH (US) 2006-05-04 WO disclosed
WO-2005019201-A2 PROCESS FOR THE PREPARATION OF 4-AMINO-3-QUINOLINECARBONITRILES WYETH HOLDINGS CORPORATION (US) 2005-03-03 WO disclosed
US-20050043537-A1 Process for preparation of 4-amino-3-quinolinecarbonitriles WYETH HOLDINGS CORPORATION (US) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033175-A1 Process for preparation of 4-amino-3-quinolinecarbonitriles BTF3, PTMS, BCAT2 SRC 1820/4885ABL1 147/4885BCR 1121/4885
US-20050043537-A1 Process for preparation of 4-amino-3-quinolinecarbonitriles BTF3, PTMS, BCAT2 SRC 1820/4885ABL1 147/4885BCR 1121/4885
US-20060116375-A1 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury TNNI3, SUCNR1, EDNRA SRC 3051/4885ABL1 1190/4885BCR 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.